Latest news

• Lundbeck drops Parkinson’s drug acquired in €905m deal

  The acquisition of Abide added a drug for Tourette’s syndrome and neuropathic pain called ABX 1431 – re-christened Lu AG06466 – and there has been some bad news on that front ... too. At the end of last week, Lundbeck said the monoacylglycerol

• Teva’s weak pipeline hit by Tourette’s drug trial failure

  Drug wasn't able to improve on placebo. Teva’s effort to reinvigorate its business with new product launches has suffered a setback after a drug for Tourette’s syndrome failed ... It’s not the first drug in the VMAT2 inhibitor class to miss the

• Lundbeck bolts on migraine drug via $1.95bn deal to buy Alder

  up. The acquisition of Alder comes after Lundbeck bought  Abide Therapeutics for $400m earlier this year – adding mid-stage drug candidate ABX-1431 for Tourette’s syndrome – and last year’s ... $1b purchase of  Prexton Therapeutics and phase 2

• Lundbeck snaps up Abide Therapeutics for $400m

  Also acquires its lead drug for Tourette’s syndrome. Danish drugmaker Lundbeck has moved to bolster its pipeline with a $400m deal to acquire Abide Therapeutics and its lead drug for ... ABX 1431 is in a phase 2a trial in Tourette’s syndrome –

• Neurocrine bags FDA approval for first tardive dyskinesia drug

  Neurocrine says it is also expecting to report results for a trial of valbenazine in children with Tourette's syndrome next month, although an earlier study in adults failed to show ... If positive, Neurocrine is hoping to start a phase III trial in